Theravance Biopharma (STU:0TB) ROE % Adjusted to Book Value : -13.27% (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Theravance Biopharma ROE % Adjusted to Book Value?

Theravance Biopharma's ROE % for the quarter that ended in Dec. 2024 was -35.42%. Theravance Biopharma's PB Ratio for the quarter that ended in Dec. 2024 was 2.67. Theravance Biopharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -13.27%.

Theravance Biopharma ROE % Adjusted to Book Value Historical Data

The historical data trend for Theravance Biopharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma ROE % Adjusted to Book Value Chart

Theravance Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

870.98

-6.59

-11.12

Theravance Biopharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-5.84	-10.50	-15.95	-12.55	-13.27

Competitive Comparison of Theravance Biopharma's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Theravance Biopharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theravance Biopharma's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Theravance Biopharma ROE % Adjusted to Book Value Calculation

Theravance Biopharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-29.69%	/	2.67
	=	-11.12%

Theravance Biopharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-35.42%	/	2.67
	=	-13.27%

Theravance Biopharma ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Theravance Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (STU:0TB) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

TBPH:USA 0TB:Germany

Address

901 Gateway Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.theravance.com

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Theravance Biopharma Headlines

No Headlines